Semaglutide improved 6-minute walk distance by 15 meters, reduced weight by 2.9%, and lowered inflammation in heart failure patients with preserved ejection fraction and obesity.
+15.1 meters walking distanceSemaglutide improved 6-minute walk distance by 15 meters, a clinically meaningful improvement for heart failure patients
What the researchers found
Semaglutide produced significant improvements in patients with HFpEF and obesity:
- 6-minute walk distance: improved by 15.1 meters vs placebo (95% CI 5.8-24.4, p = 0.002)
- Body weight: reduced by 2.9% vs placebo (95% CI -4.1 to -1.7, p = 0.001)
- C-reactive protein: reduced (indicating lower inflammation)
- Several secondary clinical endpoints also improved
- Adverse events: generally well-tolerated with no unexpected safety concerns
Why it matters
HFpEF with obesity is one of the fastest-growing heart failure phenotypes. Obesity worsens heart stiffness, exercise intolerance, and quality of life. Traditional heart failure drugs have limited benefit in HFpEF. Semaglutide addresses both the obesity and inflammation components, offering a mechanistic match for this specific patient population.
The numbers in context
- 318 patients (104 semaglutide, 214 placebo)
- 6-min walk distance: +15.1 meters (95% CI 5.8-24.4, p = 0.002)
- Weight change: -2.9% vs placebo (95% CI -4.1 to -1.7, p = 0.001)
- C-reactive protein: reduced
- No unexpected safety concerns
How the study worked
Retrospective study analyzing 318 HFpEF patients with obesity. 104 received semaglutide, 214 received placebo. Primary endpoints were changes in exercise capacity (6-minute walk distance) and weight management. Secondary endpoints included CRP levels and other clinical parameters.
Who was studied
318 obese patients with heart failure and preserved ejection fraction
What this study cannot tell us
This was a retrospective study, not a prospective randomized trial. The allocation to semaglutide vs placebo groups in a retrospective design raises questions about selection bias. The 15-meter improvement in 6-minute walk distance, while statistically significant, is modest. The study does not report heart failure hospitalization or mortality outcomes. CRP reduction does not necessarily translate to clinical benefit.
How to read the evidence
Rated moderate: reasonable sample size (318 patients) but retrospective design with some methodological questions about group allocation.
When this study was published
Published in 2024. Complements the STEP-HFpEF randomized trial data with additional real-world evidence.
The bigger picture
HFpEF with obesity is the fastest-growing heart failure type. Traditional drugs have limited benefit. Semaglutide addresses the underlying obesity and inflammation that drive this condition.
Questions still open
- Is the benefit primarily from weight loss or direct cardiac effects?
- Would longer treatment duration produce even larger exercise improvements?
Common questions
Can semaglutide help heart failure?
What is HFpEF?
Read the original research
Efficacy and safety of semaglutide in patients with heart failure with preserved ejection fraction and obesity.
Clinical cardiology, 47(5), e24283
Citation
Rehman, Ayesha; Saidullah, Shahab; Asad, Muhammad; Gondal, Umer R; Ashraf, Amna; Khan, Muhammad F; Akhtar, Waheed; Mehmoodi, Amin; Malik, Jahanzeb. (2024). Efficacy and safety of semaglutide in patients with heart failure with preserved ejection fraction and obesity.. Clinical cardiology, 47(5), e24283. https://doi.org/10.1002/clc.24283